Summary
The effects of fenoterol and salbutamol on isometric force of contraction were studied in isolated, electrically driven human papillary muscle preparations. Fenoterol increased force of contraction at concentrations of 1 µmol l−1 and higher. The maximally effective concentration of fenoterol (100 µmol l−1) increased force of contraction by about 130%. The positive inotropic effect of fenoterol was not influenced by 0.1 µmol l−1 prazosin. The beta1-selective antagonist atenolol (2 µmol l−1) and the beta2-selective antagonist ICI 118551 (1 µmol l−1) shifted the concentration-response curve of fenoterol to the right, indicating that beta1- and beta2-adrenoceptors may contribute to the positive inotropic effect of fenoterol. In contrast to fenoterol, salbutamol increased force of contraction only by about 11% at 100 µmol l−1. The results indicate that: (1) fenoterol exerts a direct positive inotropic effect in the human heart which may support the beneficial effects of the reduction of systemic vascular resistance in patients with congestive heart failure; (2) this positive inotropic effect of fenoterol is mediated by beta1- and beta2-adrenoceptors; (3) the clinically observed improvement of cardiac performance in the case of salbutamol is presumably not due to any direct positive inotropic effect.
Similar content being viewed by others
Abbreviations
- mN:
-
millinewton
- EC50 :
-
half maximal effective concentration
- SEM:
-
standard error of the mean
References
Aggestrup S, Henriksen L, Rygg IH, Lauridsen P (1980) The cardiovascular and respiratory effects of fenoterol in patients after open-heart surgery. J Cardiovasc Surg 21:409–416
Barret AM (1977) The pharmacology of atenolol. Postgrad Med J 53 (Suppl 3):58–64
Bilski A, Dorries S, Fitzgerald JD, Jessup R, Tucker H, Wale J (1980) ICI 118551 a potent β2-adrenoceptor antagonist. Br J Pharmacol 69:292P-293P
Bilski A, Halliday SE, Fitzgerald JD, Wale JL (1983) The pharmacology of a beta2-selective adrenoceptor antagonist (ICI 118551). J Cardiovasc Pharmacol 5:430–437
Bourdillon PDV, Dawson JR, Foale RA, Timmis AD, Poole-Wilson PA, Sutton GC (1980) Salbutamol in treatment of heart failure. Br Heart J 43:206–210
Brittain RT (1971) A comparison of the pharmacology of salbutamol with that of isoprenaline, orciprenaline and trimetoquinol. Postgrad Med J 47 (Suppl): 11–16
Brodde OE, Karad K, Zerkowski HR, Rohm N, Reidemeister JC (1983) Coexistence of β1- and β2-adrenoceptors in human right atrium. Direct indentification by (±)-(125J)iodocyanopindolol binding. Circ Res 53:752–758
Brown JE, McLeod AA, Shand DG (1983) Evidence for cardiac 31-3-adrenoceptors in man. J Clin Pharmacol Ther 33:424–428
Brückner R, Meyer W, Mügge A, Schmitz W, Scholz H (1984) Alpha-adrenoceptor-mediated positive inotropic effect of phenylephrine in isolated human ventricular myocardium. Eur J Pharmacol 99:345–347
Buchelt L, Rominger KL (1972) Pharmakokinetic und Metabolismus von Th 1165 A beim Menschen. Int J Clin Pharmacol 4 (Suppl):37–41
Canepa-Anson R, Dawson JR, Frankl WS, Kuan P, Sutton GC, Reuben S, Poole-Wilson PA (1982) Beta2 adrenoceptor agonists. Pharmacology, metabolic effects and arrhythmias. Eur Heart J 3 (Suppl D):129–134
Dawson JR, Poole-Wilson PA, Sutton GC (1980) Salbutamol in cardiogenic shock complicating acute myocardial infarction. Br Heart J 43:523–526
Dawson JR, Bayliss J, Norell MS, Canepa-Anson R, Kuan P, Reuben S, Poole-Wilson PA, Sutton GC (1982) Clinical studies with beta2-adrenoceptor agonists in heart failure. Eur Heart J 3 (Suppl D):135–141
Gattiker H, Rothlin M (1971) Vergleich der Wirkungen des neuen Sympathicomimeticums Th 1165a mit jenen von Isoprenalin auf den Kreislauf herzoperierter Patienten. Arzneim Forsch 21:1191–1194
Heel RC, Brogden RN, Speight TM, Avery GS (1978) Fenoterol: A review of its pharmacological properties and therapeutic efficacy in asthma. Drugs 15:3–32
Heitz A, Schwartz J, Velly J (1983)β-adrenoceptors of the human myocardium: determination of β1 and β2 subtypes by radioligand binding. Br J Pharmacol 80:711–717
Irmer M, Wollschläger H, Just H (1981) Behandlung der schweren Herzinsuffizienz mit dem Beta-Stimulator Fenoterol. Klin Wochenschr 59:639–645
Just H, Drexler H, Irmer M (1983) Therapeutic agents with combined inotropic and vasodilating properties. In: Just H, Bussmann WD (eds) Vasodilators in chronic heart failure, Springer Verlag, Berlin Heidelberg New York, pp 168–175
Kerr CR (1979) Hemodynamic effects of oral salbutamol in patients with severe left ventricular failure. Circulation 60 (Suppl II):II-41
Lai S, Savidge RS, Davies DM, Ali MM, Soni V (1972) Intravenous salbutamol and cardiogenic shock. Lancet I:853–854
Lichtlen P, Stutz R (1969) Hämodynamische Untersuchungen mit dem p-Hydroxyphenylderivat des Orciprenalins. Arzneim Forsch 19:147–149
Meinertz T, Nawrath H, Scholz H (1976) Possible role of cyclic AMP in the relaxation process of mammalian heart: Effects of dibutyryl cyclic AMP and theophylline on potassium contractures in cat papillary muscles. Naunyn Schmiedebergs Arch Pharmacol 293:129–137
Mifune J, Kuramoto K, Ueda K, Matsushita S, Kuwajima I, Sakai M, Iwasaki T, Moroki N, Murakami M (1982) Hemodynamic effects of salbutamol, an oral long-acting beta-stimulant, in patients with congestive heart failure. Am Heart J 104:1011–1015
Nayler WG, McInnes I (1972) Salbutamol and orciprenaline-induced changes in myocardial function. Cardiovasc Res 6:725–733
O'Donnell SR (1970) A selectiveβ-adrenoceptor stimulant (Th 1165a) related to orciprenaline. Eur J Pharmacol 12:35–43
O'Donnell SR, Wanstall JC (1979) The importance of choice of agonist in studies designed to predict β2:β1 adrenoceptor selectivity of antagonists from pA2 values on guinea-pig trachea and atria. Naunyn Schmiedebergs Arch Pharmacol 308:183–190
O'Donnell SR, Wanstall JC (1980) Evidence that ICI 118551 is a potent, highly beta-2 selective adrenoceptor antagonist and can be used to characterize beta-adrenoceptor populations in tissues. Life Sci 27:671–677
Poole-Wilson PA, Lewis G, Angerpointer T, Malcolm AD, Williams BT (1977) Haemodynamic effects of salbutamol and nitroprusside after cardiac surgery. Br Heart J 39:721–725
Robberecht P, Delhaye M, Taton G, De Neef P, Waelbroeck M, De Smet JM, Leclerc JL, Chatelain P, Christophe J (1983) The human heart beta-adrenergic receptors: I. Heterogeneity of the binding sites: Presence of 50% beta1- and 50% beta2-adrenergic receptors. Mol Pharmacol 24:169–173
Sharma B, Goodwin JF (1978) Beneficial effect of salbutamol on cardiac function in severe congestive cardiomyopathy. Effect on systolic and diastolic function of the left ventricle. Circulation 58:449–460
Stiles GL, Taylor S, Lefkowitz RJ (1982) Direct indentification of β1 and β2 adrenergic receptors in human left ventricular myocardium. Circulation 66 (Suppl II):II-207
Tse TF, Yu D, Wang RYC, Wong P (1978) Effect of berotec in congestive cardiac failure. VIII World Congress of Cardiology, Tokyo, Abstract No. 1269
Timmis AD, Strak SK, Chamberlain DA (1979) Haemodynamic effects of salbutamol in patients with acute myocardial infarction and severe left ventricular dysfunction. Br Med J 2:1101–1103
Waelbroeck M, Taton G, Delhaye M, Chatelain P, Camus JC, Pochet R, Leclerc JL, De Smet JM, Robberecht P, Christophe J (1983) The human heart beta-adrenergic receptors: II. Coupling of beta2-adrenergic receptors with the adenylate cyclase system. Mol Pharmacol 24:174–182
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mügge, A., Posselt, D., Reimer, U. et al. Effects of the beta2-adrenoceptor agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium. Klin Wochenschr 63, 26–31 (1985). https://doi.org/10.1007/BF01537483
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01537483